Article Data

  • Views 858
  • Dowloads 134

Original Research

Open Access

The mechanism of miR-143-3p regulating FGF-9 in the proliferation, invasion

  • Wang Yan1,*,

1Tangshan People’s Hospital, 063000 Tangshan, Hebei, China

DOI: 10.22514/ejgo.2024.009 Vol.45,Issue 1,February 2024 pp.55-62

Submitted: 29 August 2022 Accepted: 29 November 2022

Published: 15 February 2024

*Corresponding Author(s): Wang Yan E-mail:


The study aimed at exploring the miR-143-3p expression and the mechanism involved in ovarian cancer development. RT-qPCR (Quantitative Real-time PCR) served for the detection of the miR-143-3p level in different ovarian carcinoma cells. Then miR-143-3p underwent transfection and presented overexpression in ovarian carcinoma cells. 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay, flat cloning experiment, Transwell invasion assay and scratch test served for the evaluation of the influences of miR-143-3p on ovarian cancer cell biological behavior. The candidate target genes were screened by using bioinformatics method. The double luciferase assay and Western blot together assessed the regulatory effect of miR-143-3p. Relative to the control group (NC), the overexpressed group presented significantly reduced ovarian cancer cell growth (p < 0.01). The results indicated the inhibitory impact of miR-143-3p overexpression on the invasion and migration of ovarian cancer 3AO and SKOV3 cells. Bioinformatics analysis confirmed FGF-9 (Fibroblast Growth Factor 9) as one of target gene of miR-143-3p. Double luciferase assay also attested the direct negative regulatory impact of miR-143-3p on FGF-9 (p < 0.05). The miR-143-3p overexpression significantly lowered the protein level of FGF-9 in 3AO and SKOV3 cells (p < 0.001). miR-143-3p overexpression negatively regulated the proliferation, invasion and migration abilities of ovarian carcinoma cells, as well as the FGF-9 protein expression.


miR-143-3p; Ovarian carcinoma; Proliferation; Invasion; Migration; FGF-9

Cite and Share

Wang Yan. The mechanism of miR-143-3p regulating FGF-9 in the proliferation, invasion. European Journal of Gynaecological Oncology. 2024. 45(1);55-62.


[1] Penny SM. Ovarian cancer: an overview. Radiologic Technology. 2020; 91: 561–575.

[2] Wang Y, Meng F, Liu Y, Chen X. Expression of HPIP in epithelial ovarian carcinoma: a clinicopathological study. OncoTargets and Therapy. 2017; 10: 95–100.

[3] Kossaï M, Leary A, Scoazec J, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018; 85: 41–49.

[4] Bogani G, Borghi C, Leone Roberti Maggiore U, Ditto A, Signorelli M, Martinelli F, et al. Minimally invasive surgical staging in early-stage ovarian carcinoma: a systematic review and meta-analysis. Journal of Minimally Invasive Gynecology. 2017; 24: 552–562.

[5] Coughlan AY, Testa G. Exploiting epigenetic dependencies in ovarian cancer therapy. International Journal of Cancer. 2021; 149: 1732–1743.

[6] Zhao L, Guo H, Chen X, Zhang W, He Q, Ding L, et al. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. European Journal of Pharmacology. 2022; 927: 175071.

[7] Wang Y, Huang Z, Li B, Liu L, Huang C. The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer. Frontiers in Endocrinology. 2022; 13: 863541.

[8] Záveský L, Jandáková E, Weinberger V, Hanzíková V, Slanař O, Kohoutová M. Ascites in ovarian cancer: MicroRNA deregulations and their potential roles in ovarian carcinogenesis. Cancer Biomarkers. 2022; 33: 1–16.

[9] Chen SN, Chang R, Lin LT, Chen CU, Tsai HW, Wen ZH. MicroRNA in ovarian cancer: biology, pathogenesis, and therapeutic opportunities. International Journal of Environmental Research and Public Health. 2019; 16: 1510.

[10] Ma L, Liang L, Zhou D, Wang S. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4. Neoplasma. 2021; 68: 165–173.

[11] Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, et al. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. Journal of Experimental & Clinical Cancer Research. 2020; 39: 3.

[12] Cao J, Huo P, Cui K, Wei H, Cao J, Wang J, et al. Follicular fluid-derived exosomal miR-143-3p/miR-155-5p regulate follicular dysplasia by modulating glycolysis in granulosa cells in polycystic ovary syndrome. Cell Communication and Signaling. 2022; 20: 61.

[13] He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, et al. MiRNA-based biomarkers, therapies, and resistance in cancer. International Journal of Biological Sciences. 2020; 16: 2628–2647.

[14] Wang H, Deng Q, Lv Z, Ling Y, Hou X, Chen Z, et al. N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1. Molecular Cancer. 2019; 18: 181.

[15] Tang J, Pan H, Wang W, Qi C, Gu C, Shang A, et al. MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer. Clinical and Translational Oncology. 2021; 23: 2323–2334.

[16] Zhang J, Huang J, Chen W, Hu Z, Wang X. miR-143-3p Targets lncRNA PSMG3-AS1 to Inhibit the Proliferation of Hepatocellular Carcinoma Cells. Cancer Management and Research. 2020; 12: 6303–6309.

[17] Jiang Z. Molecular mechanism of miR-143-3p regulating lung metastasis of human osteosarcoma (OS) [master’s thesis]. Suzhou University. 2015.

[18] He Z, Yi J, Liu X,Chen J, Han S, Jin L, et al. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Molecular Cancer. 2016; 15: 51.

[19] Schütz LF, Schreiber NB, Gilliam JN, Cortinovis C, Totty ML, Caloni F, et al. Changes in fibroblast growth factor 9 mRNA in granulosa and theca cells during ovarian follicular growth in dairy cattle. Journal of Dairy Science. 2016; 99: 9143–9151.

[20] Totty ML, Morrell BC, Spicer LJ. Fibroblast growth factor 9 (FGF9) regulation of cyclin D1 and cyclin-dependent kinase-4 in ovarian granulosa and theca cells of cattle. Molecular and Cellular Endocrinology. 2017; 440: 25–33.

[21] Zhang YQ, Miao JW. The role of FGF9 in ovarian cancer. Progress in Obstetrics and Gynecology. 2011; 20: 660–662.

[22] Abdel-Rahman WM, Kalinina J, Shoman S, Eissa S, Ollikainen M, Elomaa O, et al. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous β-cateiiin. Human Mutation. 2008; 29: 390–397.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time